Exploration of Targeted Anti-tumor Therapy

Table 1. Characteristics of the studies included in the meta-analysis.

Study (author/year)	Study type	Number of patients [immune checkpoint inhibitor (ICI) group/control]	Cancer type	Treatment regimen	Primary outcome measure
CONTINUUM	Phase III, randomized controlled trial (RCT)	423 total; 209 ICI/214 control	Locally advanced nasopharyngeal carcinoma (LA NPC)	Chemotherapy induction (gemcitabine + cisplatin) followed by cisplatin radiotherapy versus standard + sintilimab (ICI)	Event-free survival
DIPPER	Phase III, RCT	450 randomized (226 ICI/224 control); 426 included in safety analysis (205 ICI/221 control)	LA NPC	Chemotherapy induction + concurrent chemotherapy, then camrelizumab versus observation	Event-free survival
Phase II toripalimab trial	Phase II, RCT	149 total; 99 ICI/50 control	LA NPC	Neoadjuvant toripalimab versus placebo, followed by concurrent chemoradiotherapy, then adjuvant toripalimab versus placebo	Progression-free survival
Total	-	998 total; 513 ICI/485 control	-	-	-

Return to article view

Supplementary materials

Supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/1002403_sup_1.pdf.

Declarations

Author contributions

RS: Conceptualization, Data curation, Formal analysis, Investigation, Writing—original draft, Writing—review & editing, Visualization. JT: Data curation. S Afifi: Formal analysis. TK: Formal analysis. HA: Validation, Investigation. RKN: Data curation. DTJ: Validation. KD: Writing—original draft. KN: Writing—original draft. KF: Writing—review & editing. S Aamer: Writing—review & editing. YMM: Writing—review & editing. JLB: Supervision. KZT: Conceptualization, Software, Supervision. All authors read and approved the submitted version.

Conflicts of interest

Author Kyaw Zin Thein served on the advisory board for Coherus Biosciences, Pfizer, EMD Serono, Eisai, and Janssen Biotech; provided consulting and served on the speaker bureau for Coherus Biosciences and Eisai; and received honoraria from Targeted Oncology, MD Outlook, Aptitude Health, Cardinal Health, IDEOlogy Health, Inizio, OMNI-Oncology, GSK Consulting, Roundtable Oncology, Curio Science, and Onviv Expert Network, not related to this manuscript. All other authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

All relevant data are contained within the manuscript. All datasets analyzed for this study are included in the manuscript and the supplementary files. The datasets supporting the findings of this study are available from the corresponding author upon reasonable request.

Funding

The authors declare that no funding was provided to perform this research activity.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Chang ET, Ye W, Zeng YX, Adami HO. The Evolving Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiol Biomark Prev. 2021;30:1035–47. [DOI] [PubMed]

Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 2007;9:1–24. [DOI] [PubMed]

Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version [Internet]. [cited 2025 Jan 18]. Available from: https://www.cancer.gov/types/head-and-neck/hp/adult/nasopharyngeal-treatment-pdq

Meng L, Wu H, Wu J, Ding P, He J, Sang M, et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024;15:3. [DOI] [PubMed] [PMC]

Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8:320. [DOI] [PubMed] [PMC]

American Cancer Society. Immunotherapy for nasopharyngeal cancer [Internet]. American Cancer Society; c2026 [cited 2025 Jan 20]. Available from: https://www.cancer.org/cancer/types/nasopharyngeal-cancer/treating/immunotherapy.html

American Cancer Society. Immune checkpoint inhibitors and their side effects [Internet]. American Cancer Society; c2026 [cited 2025 Jan 20]. Available from: https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html

Mayo Clinic. Immune checkpoint inhibitors and thyroid dysfunction: a case from the endocrine teaching clinics [Internet]. Mayo Foundation for Medical Education and Research (MFMER); c1998-2026 [cited 2025 Feb 01]. Available from: https://www.mayoclinic.org/medical-professionals/endocrinology/news/immune-checkpoint-inhibitors-and-thyroid-dysfunction-a-case-from-the-endocrine-teaching-clinics/mcc-20439104

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. [DOI] [PubMed] [PMC]

10.

Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403:2720–31.

11.

Liang YL, Liu X, Shen LF, Hu GY, Zou GR, Zhang N, et al. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma. JAMA. 2025;333:1589–98. [DOI] [PubMed] [PMC]

12.

Liu SL, Li XY, Yang JH, Wen DX, Guo SS, Liu LT, et al. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2024;25:1563–75. [DOI] [PubMed]

13.

Cai M, Wang Y, Ma H, Yang L, Xu Z. Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma. Cancer Treat Rev. 2024;131:102840. [DOI] [PubMed]

14.

Liu X, Yi Y. Recent updates on Sintilimab in solid tumor immunotherapy. Biomark Res. 2020;8:69. [DOI] [PubMed] [PMC]

15.

Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020;10:594558. [DOI] [PubMed] [PMC]

16.

Ma M, Qi H, Hu C, Xu Z, Wu F, Wang N, et al. The binding epitope of sintilimab on PD-1 revealed by AbMap. Acta Biochim Biophys Sin. 2021;53:628–35. [DOI] [PubMed]

17.

Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, et al. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024;73:60. [DOI] [PubMed] [PMC]

18.

Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther. 2020;14:1177–89. [DOI] [PubMed] [PMC]

19.

Liu K, Tan S, Jin W, Guan J, Wang Q, Sun H, et al. N‐glycosylation of PD‐1 promotes binding of camrelizumab. EMBO Rep. 2020;21:e51444. [DOI] [PubMed] [PMC]

20.

Lin Y, Lin Y, Zhong X, Chen Q, Tang S, Chen J. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient. Front Oncol. 2023;13:1280208. [DOI] [PubMed] [PMC]

21.

Lu D, Yao J, Yuan G, Gao Y, Zhang J, Guo X. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. Oncologist. 2022;27:e126–32. [DOI] [PubMed] [PMC]

22.

Liu S, Zhao Q, Zheng Z, Liu Z, Meng L, Dong L, et al. Status of Treatment and Prophylaxis for Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer. Front Oncol. 2021;11:642575. [DOI] [PubMed] [PMC]

23.

King SN, Dunlap NE, Tennant PA, Pitts T. Pathophysiology of Radiation-Induced Dysphagia in Head and Neck Cancer. Dysphagia. 2016;31:339–51. [DOI] [PubMed] [PMC]

24.

Srivastava A, Nogueras-Gonzalez GM, Geng Y, Singh J, Myers JN, Li Y, et al. Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials. J Immunother Precis Oncol. 2024;7:24–40. [DOI] [PubMed] [PMC]

25.

Edner NM, Carlesso G, Rush JS, Walker LSK. Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov. 2020;19:860–83. [DOI] [PubMed]

26.

Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226. [DOI] [PubMed] [PMC]

27.

Francisco LM, Sage PT, Sharpe AH. The PD‐1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42. [DOI] [PubMed] [PMC]

28.

Wang JH. Why the Outcome of Anti‐Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers. BioEssays. 2020;42:e2000024. [DOI] [PubMed] [PMC]

29.

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). version 4.03. National Cancer Institute; 2010. pp. 194.

30.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–68. [DOI] [PubMed] [PMC]